- Leap Therapeutics Inc ASCO GI 2024 DeFianCe Study Webcast TranscriptJan 23, 2024
- Leap Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Leap Therapeutics Inc at Robert W Baird Global Healthcare Conference TranscriptSep 13, 2023
- Leap Therapeutics Inc at HC Wainwright Investment Conference - New York TranscriptSep 11, 2023
- Leap Therapeutics Inc Annual Shareholders Meeting TranscriptJun 16, 2023
- Leap Therapeutics Inc Acquires Flame Biosciences TranscriptJan 17, 2023
- Leap Therapeutics Inc at Piper Sandler Healthcare Conference TranscriptNov 29, 2022
- Leap Therapeutics Inc - R&D Day TranscriptJul 12, 2022
- Leap Therapeutics Inc ASCO GI 2022 DisTinGuish Study Conference Call TranscriptJan 21, 2022
- Leap Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Leap Therapeutics Inc ESMO 2021 DisTinGuish Study Conference Call TranscriptSep 17, 2021
- Leap Therapeutics Inc at Ladenburg Thalmann Virtual Healthcare Conference TranscriptJul 14, 2021
- Leap Therapeutics Inc at Raymond James Human Health Innovation Conference (Virtual) TranscriptJun 21, 2021
- Leap Therapeutics Inc DKN-01 Clinical Data Conference Call TranscriptMar 22, 2021
- Leap Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Leap Therapeutics Inc Annual Shareholders Meeting TranscriptJun 16, 2020
- Leap Therapeutics, Inc. - Special Call TranscriptApr 23, 2020
- Leap Therapeutics, Inc. - Special Call TranscriptAug 06, 2019
Leap Therapeutics Inc Annual Shareholders Meeting Transcript
Good morning, ladies and gentlemen. I'm Douglas Onsi, Chief Executive Officer and President of Leap Therapeutics, Inc., and it's my pleasure to welcome all of you to our virtual Annual Meeting. It is 11:30 AM on June 16, 2023. And in accordance with the Notice of Annual Meeting of Stockholders, I call to order this Annual Meeting of Stockholders of Leap Therapeutics.
On the virtual meeting platform, each stockholder has been granted access to an agenda and rules of conduct for the meeting. I expect compliance of these rules, especially if you intend to comment or ask a question at the meeting.
The items of business before the meeting are: one, the proposed election of three Class III directors nominated by our Board of Directors, Joseph Loscalzo, Nissim Mashiach, and Christopher Mirabelli, each to serve for a term ending in 2026, or until his successor has been duly elected and qualified; two, the proposal to approve an advisory vote on executive compensation paid to our named executive officers; three, to indicate, on an
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)